Literature DB >> 7238264

Hyperprolactinemia in portal systemic encephalopathy.

C J McClain, J P Kromhout, M K Elson, D H Van Thiel.   

Abstract

The accumulation of false neurotransmitters such as octopamine and depletion of true neurotransmitters such as dopamine have been purported to play a pathogenetic role in portal systemic encephalopathy (PSE). Therefore, we measured plasma prolactin, a known sensitive indicator of functional dopamine activity in man, in an attempt to evaluate dopaminergic function in 21 patients with alcoholic liver disease and PSE and several control groups. Subjects with PSE had markedly elevated prolactin levels (P less than 0.01) when compared to all control groups. Moreover, patients with PSE were divisible into two groups, 12 having mildly increased prolactin levels and 9 having markedly elevated levels. Although the degree of PSE was similar in both groups, those PSE patients with the higher prolactin values had significantly greater derangement of serum albumin, bilirubin, prothrombin time, and also had a higher mortality (100%). These data: (1) provide evidence consistent with the hypothesis of altered neurotransmitter function in individuals with chronic alcoholic liver disease, particularly those manifesting evidence of PSE; (2) suggest that altered dopamine function in chronic liver disease may have pathophysiologic significance as judged by altered hormone release; (3) demonstrate that a markedly elevated plasma prolactin level in individuals with PSE carries an ominous prognosis; and (4) suggest a possible role for the plasma prolactin in the selection and monitoring of PSE patients who are to be treated with agents aimed at correcting neurotransmitter abnormalities.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7238264     DOI: 10.1007/bf01308378

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  28 in total

Review 1.  Pathogenesis of hepatic coma.

Authors:  L Zieve; D M Nicoloff
Journal:  Annu Rev Med       Date:  1975       Impact factor: 13.739

2.  Neuropharmacological intervention on the pituitary-hypothalamic relationship.

Authors:  J Tuomisto
Journal:  Ann Clin Res       Date:  1978

3.  Can hepatic coma be caused by a reduction of brain noradrenaline or dopamine?

Authors:  L Zieve; R L Olsen
Journal:  Gut       Date:  1977-09       Impact factor: 23.059

4.  Successful use of bromocriptine in the treatment of a patient with chronic portasystemic encephalopathy.

Authors:  M Y Morgan; A Jakobovits; A Elithorn; I M James; S Sherlock
Journal:  N Engl J Med       Date:  1977-04-07       Impact factor: 91.245

5.  Chronic hepatic encephalopathy. Long-term therapy with a branched-chain amino-acid-enriched elemental diet.

Authors:  H Freund; N Yoshimura; J E Fischer
Journal:  JAMA       Date:  1979-07-27       Impact factor: 56.272

6.  Octopamine plasma levels and hepatic encephalopathy: a re-appraisal of the problem.

Authors:  F Rossi-Fanelli; C Cangiano; A Attili; M Angelico; A Cascino; L Capocaccia; R Strom; C Crifó
Journal:  Clin Chim Acta       Date:  1976-03-15       Impact factor: 3.786

7.  L-dopa in hepatic coma.

Authors:  J E Fischer; F J Funovics; H A Falcao; R I Wesdorp
Journal:  Ann Surg       Date:  1976-04       Impact factor: 12.969

8.  Treatment of chronic portal systemic encephalopathy with bromocriptine: a double-blind controlled trial.

Authors:  M Uribe; A Farca; M A Márquez; G Garcĭa-Ramos; L Guevara
Journal:  Gastroenterology       Date:  1979-06       Impact factor: 22.682

9.  Reversal of ammonia coma in rats by L-dopa: a peripheral effect.

Authors:  L Zieve; W M Doizaki; R F Derr
Journal:  Gut       Date:  1979-01       Impact factor: 23.059

10.  Influences of exogenous intake and nitrogen balance on plasma and brain aromatic amino acid concentrations.

Authors:  H M Rosen; P B Soeters; J H James; J Hodgman; J E Fisher
Journal:  Metabolism       Date:  1978-04       Impact factor: 8.694

View more
  8 in total

Review 1.  Biochemical diagnosis in prolactinomas: some caveats.

Authors:  Stephan Petersenn
Journal:  Pituitary       Date:  2020-02       Impact factor: 4.107

2.  Amino acids in hepatic coma.

Authors:  J E Fischer
Journal:  Dig Dis Sci       Date:  1982-02       Impact factor: 3.199

Review 3.  Pathogenesis of hepatic encephalopathy.

Authors:  L Zieve
Journal:  Metab Brain Dis       Date:  1987-09       Impact factor: 3.584

Review 4.  Male hypogonadism in cirrhosis and after liver transplantation.

Authors:  C Foresta; M Schipilliti; F A Ciarleglio; A Lenzi; D D'Amico
Journal:  J Endocrinol Invest       Date:  2008-05       Impact factor: 4.256

5.  Does hyperprolactinemia affect hepatic regeneration independent of sex steroids?

Authors:  D Kahn; J S Gavaler; L Makowka; P Chapchap; V Mazzaferro; A Casavilla; M S Smith; P K Eagon; T E Starzl; D H Van Thiel
Journal:  J Lab Clin Med       Date:  1988-11

6.  Lack of dissociation of prolactin responses to thyrotropin releasing hormone and metoclopramide in chronic alcoholic men.

Authors:  D H Van Thiel; J S Gavaler; A Sanghvi
Journal:  J Endocrinol Invest       Date:  1982 Sep-Oct       Impact factor: 4.256

7.  Failure of nomifensine to reduce serum prolactin levels in patients with hepatic encephalopathy.

Authors:  A Masala; S Alagna; P P Rovasio; A Deplano; V Anania; L Chiandussi; M Langer
Journal:  J Endocrinol Invest       Date:  1985-02       Impact factor: 4.256

8.  Serum prolactin in patients with liver disease in comparison with healthy adults: A preliminary cross-sectional study.

Authors:  Sumit Kant Jha; Sridharan Kannan
Journal:  Int J Appl Basic Med Res       Date:  2016 Jan-Mar
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.